Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Jawaharlal Nehru Centre For Advanced Scientific Research currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, which means that each pending matter is being reviewed by a different official. The prosecution is also divided between 2 distinct art units. This indicates that the center's current biotechnology research is being evaluated across 2 different specialized technical groups within the patent office.
The busiest examiner for the portfolio is CHENG, KAREN, who is responsible for 1 pending office action. This accounts for 1 of the 2 total pending actions for the organization. Because each of the 2 distinct examiners is handling 1 pending action, the workload is balanced between them. Practitioners should be prepared to manage 2 different examiner perspectives across 2 distinct art units. This structure suggests that the pending Biotechnology & Pharmaceuticals applications cover diverse technical aspects that necessitate 2 separate art unit assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, KAREN | 1 | 76.3% | +26.7% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006578 | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | RZECZYCKI, PHILLIP MATTHEW | 5d overdue |
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565911 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | CHENG, KAREN | 1623 | §102§103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18006578 | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Non-Final OA | 5d overdue | Pending | Jan 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial